A PYMNTS Company

FTC’s Second Request for additional information on Spectrum’s offer for Allos

By  |  May 10, 2012

The FTC has made a Second Request, for additional information and documentary material, on Spectrum Pharmaceutical’s proposed acquisition of Allos Therapeutics. As a result, Spectrum has extended the offer period for its tender offer to purchase all outstanding shares of common stock, from May 10 to May 24.

Spectrum is a biotech company that acquires, develops, and markets oncology and hematology drugs. Allos develops and commercializes cancer treatments.

Full content: MarketWatch

 

Related content: New Horizontal Merger Guidelines Indicate Greater Scrutiny of High Tech and Pharmaceutical Transactions (Janet McDavid & Eric Stock, Hogan Lovells)

 

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.